Breaking Finance News

Hikma Pharmaceuticals PLC (LON:HIK) target price lowered to 1,350.00GBX, released a report earlier today by Morgan Stanley

Stating a potential upside of 0.20%, Morgan Stanley bumped down the target of Hikma Pharmaceuticals PLC (LON:HIK) to 1,350.00GBX

Previously on 8/17/2017, Numis reported about Hikma Pharmaceuticals PLC (LON:HIK) maintained the target price at 1,560.00GBX. At the time, this indicated a possible upside of 0.29%.

Only yesterday Hikma Pharmaceuticals PLC (LON:HIK) traded -5.97% lower at 1,129.00GBX. Hikma Pharmaceuticals PLC’s 50-day average is 1,376.46GBX and its two hundred day average is 1,756.82GBX. With the last stock price close down -36.31% from the 200-day moving average, compared to the S&P 500 which has increased 0.05% over the same time. 1,474,853 shares of HIK traded hands, up from an average trading volume of 771,284

See Chart Below

Hikma Pharmaceuticals PLC (LON:HIK)

Hikma Pharmaceuticals PLC has a one year low of 1,101.00GBX and a one year high of 2,346.00GBX with a price-earnings ratio of 16.22 The company’s market cap is currently 0 GBX.

In addition to Morgan Stanley reporting its stock price target, a total of 9 brokerages have released a research note on HIK. The one year target is 32.71GBX with four brokerages rating the company a strong buy, six brokerages rating the company a buy, zero equity analysts rating the company a hold, zero equity analysts rating the stock a underperform, and finally 0 brokers rating the stock a sell.

About Hikma Pharmaceuticals PLC (LON:HIK)

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company's segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets. The Company sells specialized generic injectable products across the globe. It also sells non-injectable generic products in the United States, supplying over 260 products in approximately 110 different dosage strengths and forms. The Company's other businesses comprise Arab Medical Containers, a manufacturer of plastic specialized medicinal sterile containers, International Pharmaceuticals Research Centre, which conducts bio-equivalency studies, and the active pharmaceutical ingredient (API) manufacturing division of Hikma Pharmaceuticals Limited Jordan.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.